Kura Oncology enters co-promotion agreement with Kyowa Kirin for ziftomenib in AML

Kura Oncology, Inc.

Co-promotion and medical affairs agreement with Kyowa Kirin US for ziftomenib, a menin inhibitor for AML, dated June 27, 2025.
Kyowa Kirin US will co-promote for up to a certain percentage of US details; parties share costs equally.
Kura leads US medical affairs; parties jointly develop health economics and outcomes research strategy.
Term continues until mutual cessation of US commercialization or expiration of Collaboration Agreement term (up to 10 years after first commercial sale).
Agreement automatically terminates with Collaboration Agreement; either party can terminate for uncured material breach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.